<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00262470</url>
  </required_header>
  <id_info>
    <org_study_id>008397</org_study_id>
    <secondary_id>UL1TR000445</secondary_id>
    <nct_id>NCT00262470</nct_id>
  </id_info>
  <brief_title>Treatment of Orthostatic Intolerance</brief_title>
  <official_title>Treatment of Orthostatic Intolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Satish R. Raj</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed to study the effects of various mechanistically unique medications in
      controlling excessive increases in heart rate with standing and in improving the symptoms of
      orthostatic intolerance in patients with this disorder.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1997</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in heart rate with standing</measure>
    <time_frame>1-4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sitting heart rate</measure>
    <time_frame>1-4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standing heart rate</measure>
    <time_frame>1-4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>1-4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in blood pressure with standing</measure>
    <time_frame>1-4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Orthostatic symptoms score</measure>
    <time_frame>Baseline, 2h, 4h</time_frame>
  </secondary_outcome>
  <number_of_arms>20</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Tachycardia</condition>
  <condition>Chronic Orthostatic Intolerance</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acetazolamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atomoxetine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NO Drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clonidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entacapone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indomethacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isosorbide Dinitrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mecamylamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Memantine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melatonin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Midodrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modafinil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Octreotide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>14</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (lactose tablet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propranolol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>16</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sertraline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>17</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal Saline (0.9%) 1 liter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>18</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drinking Water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dead Space Breathing Device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abdominal Binder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abdominal binder with inflatable pressure over abdomen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <description>250 mg PO x 1</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Diamox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomoxetine</intervention_name>
    <description>10-40 mg PO x 1 dose</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Strattera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NO Drug</intervention_name>
    <description>No intervention - just monitoring</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine</intervention_name>
    <description>Clonidine 0.05-0.3 mg PO x 1 dose</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Catapres</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entacapone</intervention_name>
    <description>Entacapone 200-400 mg PO x 1 dose</description>
    <arm_group_label>5</arm_group_label>
    <other_name>Comtan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entacapone &amp; Propranolol</intervention_name>
    <description>Entacapone 200-400 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose</description>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>15</arm_group_label>
    <other_name>Comtan</other_name>
    <other_name>Inderal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomoxetine &amp; Propranolol</intervention_name>
    <description>Atomoxetine 10-40 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>15</arm_group_label>
    <other_name>Strattera</other_name>
    <other_name>Inderal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>Indomethacin 25-50 mg PO x 1 dose</description>
    <arm_group_label>6</arm_group_label>
    <other_name>Indocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mecamylamine</intervention_name>
    <description>mecamylamine 1.25-5 mg PO x 1 dose</description>
    <arm_group_label>8</arm_group_label>
    <other_name>inversine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isosorbide Dinitrate</intervention_name>
    <description>Isosorbide dinitrate 5-20 mg PO x 1 dose</description>
    <arm_group_label>7</arm_group_label>
    <other_name>Isordil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>melatonin 3 mg PO x 1 dose</description>
    <arm_group_label>10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine</intervention_name>
    <description>midodrine 2.5-10 mg PO x 1 dose</description>
    <arm_group_label>11</arm_group_label>
    <other_name>pro-amatine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil</intervention_name>
    <description>modafinil 100-200 mg PO x 1 dose</description>
    <arm_group_label>12</arm_group_label>
    <other_name>provigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide</intervention_name>
    <description>octreotide 12.5-50 mcg Subcutaneous x 1 dose</description>
    <arm_group_label>13</arm_group_label>
    <other_name>sandostatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>lactose tablet x 1 pill</description>
    <arm_group_label>14</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Propranolol 10-80 mg PO x 1-2 dose</description>
    <arm_group_label>15</arm_group_label>
    <other_name>Inderal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil &amp; Propranolol</intervention_name>
    <description>Modafinil 100-200 mg PO x 1 dose AND Propranolol 20 mg PO x 1 dose</description>
    <arm_group_label>12</arm_group_label>
    <arm_group_label>15</arm_group_label>
    <other_name>Provigil</other_name>
    <other_name>Inderal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>sertraline 25-50 mg PO x 1 dose</description>
    <arm_group_label>16</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IV Saline</intervention_name>
    <description>1 liter IV over 2 hours</description>
    <arm_group_label>17</arm_group_label>
    <other_name>NaCl solution (0.9%)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Drinking Water</intervention_name>
    <description>16 fluid ounces</description>
    <arm_group_label>18</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Breathing Device</intervention_name>
    <description>Breathing through a dead space tube</description>
    <arm_group_label>19</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>memantine</intervention_name>
    <description>memantine 5-20 mg PO x 1 dose</description>
    <arm_group_label>9</arm_group_label>
    <other_name>Namenda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Abdominal binder</intervention_name>
    <description>Using large blood pressure cuffs linked together, they are wrapped around the subjects abdomen and inflated to generate increased pressure to below tolerably threshold.</description>
    <arm_group_label>Abdominal Binder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic symptoms (&gt; 6 months) with standing upright

        Exclusion Criteria:

          -  Obvious cause of hypovolemia or drugs that could worsen tachycardia

          -  Chronic severe medical conditions such as cancer or ischemic heart disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Satish R Raj, MD MSCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Autonomic Dysfunction Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mc.vanderbilt.edu/root/vumc.php?site=adc</url>
    <description>Vanderbilt University Autonomic Dysfunction Center website</description>
  </link>
  <results_reference>
    <citation>Raj SR, Black BK, Biaggioni I, Harris PA, Robertson D. Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. Circulation. 2005 May 31;111(21):2734-40. Epub 2005 May 23.</citation>
    <PMID>15911704</PMID>
  </results_reference>
  <results_reference>
    <citation>Raj SR, Black BK, Biaggioni I, Paranjape SY, Ramirez M, Dupont WD, Robertson D. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. Circulation. 2009 Sep 1;120(9):725-34. doi: 10.1161/CIRCULATIONAHA.108.846501. Epub 2009 Aug 17.</citation>
    <PMID>19687359</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2005</study_first_submitted>
  <study_first_submitted_qc>December 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2005</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Satish R. Raj</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine &amp; Pharmacology</investigator_title>
  </responsible_party>
  <keyword>tachycardia</keyword>
  <keyword>sinus tachycardia</keyword>
  <keyword>postural tachycardia syndrome (POTS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Orthostatic Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Mecamylamine</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
    <mesh_term>Midodrine</mesh_term>
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Memantine</mesh_term>
    <mesh_term>Entacapone</mesh_term>
    <mesh_term>Indomethacin</mesh_term>
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Armodafinil</mesh_term>
    <mesh_term>Acetazolamide</mesh_term>
    <mesh_term>Isosorbide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

